{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:40:26Z","timestamp":1788921626233,"version":"build-2803163510"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1999,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Enrofloxacin (2.5 mg\/kg of body weight) and danofloxacin (1.25 mg\/kg) were administered subcutaneously to ruminating calves (<jats:italic>n<\/jats:italic>= 8) fitted with subcutaneous tissue cages. Concentrations of enrofloxacin, its metabolite ciprofloxacin, and danofloxacin in blood (plasma), tissue cage exudate (following intracaveal injection of 0.3 ml of 1% [vol\/wt] carrageenan), and bronchial secretions were measured by high-performance liquid chromatography (HPLC) and microbiological assay (enrofloxacin plus ciprofloxacin and danofloxacin). Mean maximum concentrations (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) \u00b1 standard deviations of enrofloxacin (0.24 \u00b1 0.08 \u03bcg\/ml), ciprofloxacin (0.11 \u00b1 0.03 [total, 0.34 \u00b1 0.10] \u03bcg\/ml), and danofloxacin (0.23 \u00b1 0.05 \u03bcg\/ml) were detected in the plasma of calves by HPLC. The<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>were 0.49 \u00b1 0.17 \u03bcg\/ml (enrofloxacin equivalents) and 0.24 \u00b1 0.03 \u03bcg\/ml (danofloxacin) when they were measured by microbiological assay. Mean<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>in exudate (HPLC) were 0.18 \u00b1 0.07 \u03bcg\/ml (enrofloxacin), 0.10 \u00b1 0.04 \u03bcg\/ml (ciprofloxacin), 0.27 \u00b1 0.09 \u03bcg\/ml (enrofloxacin plus ciprofloxacin), and 0.19 \u00b1 0.05 \u03bcg\/ml (danofloxacin), and concentrations in exudate exceeded those in plasma from 8 h (enrofloxacin and ciprofloxacin) or 6 h (danofloxacin) after drug administration. The<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>were 0.34 \u00b1 0.09 \u03bcg\/ml (enrofloxacin equivalents) and 0.22 \u00b1 0.04 \u03bcg\/ml (danofloxacin) in exudate when they were measured by the microbiological assay. The maximum mean concentration achieved in bronchial secretions (HPLC) were 0.07 \u00b1 0.04 \u03bcg\/ml (enrofloxacin), 0.04 \u00b1 0.07 \u03bcg\/ml (ciprofloxacin), 0.10 \u00b1 0.05 \u03bcg\/ml (enrofloxacin plus ciprofloxacin), and 0.12 \u00b1 0.09 \u03bcg\/ml (danofloxacin). The maximum mean concentration in bronchial secretions from a limited number of animals from which samples were available for microbiological assay were 0.27 \u00b1 0.11 \u03bcg\/ml (<jats:italic>n<\/jats:italic>= 4 [enrofloxacin equivalents]) and 0.14 \u00b1 0.02 \u03bcg\/ml (<jats:italic>n<\/jats:italic>= 3 [danofloxacin]). With predictive models of efficacy (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>\/MIC and area under the concentration-time curve\/MIC ratios in plasma) for<jats:italic>Pasteurella multocida<\/jats:italic>(MIC of enrofloxacin, 0.06 \u03bcg\/ml [24]; MIC of danofloxacin, 0.06 \u03bcg\/ml [6]), enrofloxacin produced scores of 8.17 and 52.00, respectively, compared to those of danofloxacin, which were 4.02 and 23.05, respectively. With the dosing rates recommended in some markets by manufacturers, enrofloxacin and danofloxacin achieved concentrations above the MICs for important pathogenic organisms in plasma, tissue cage exudate, and bronchial secretion. Since fluoroquinolones display concentration-dependent activities,<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>\/MIC ratios may be critical to efficacy. In the United States enrofloxacin is currently the only fluoroquinolone licensed for food animals and dosages for acute respiratory disease are 2.5 to 5 mg\/kg for 3 days or 7.5 to 12.5 mg\/kg once. The higher dosages on a single occasion are likely to confer<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>\/MIC ratios that are associated with greater clinical efficacy.<\/jats:p>","DOI":"10.1128\/aac.43.8.1988","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:35:20Z","timestamp":1539045320000},"page":"1988-1992","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":87,"title":["Pharmacokinetics of Enrofloxacin and Danofloxacin in Plasma, Inflammatory Exudate, and Bronchial Secretions of Calves following Subcutaneous Administration"],"prefix":"10.1128","volume":"43","author":[{"given":"Quintin","family":"McKellar","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Veterinary Pharmacology, University of Glasgow Veterinary School, Glasgow, United Kingdom,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gibson","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Veterinary Pharmacology, University of Glasgow Veterinary School, Glasgow, United Kingdom,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Monteiro","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Veterinary Pharmacology, University of Glasgow Veterinary School, Glasgow, United Kingdom,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Bregante","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Department of Pharmacology and Physiology, University of Zaragoza, Zaragoza, Spain2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"165","article-title":"Accumulation of enrofloxacin and its active metabolite ciprofloxacin in lung tissues of the dog.","volume":"10","author":"Boothe D.","year":"1996","unstructured":"Boothe D. Hawkins E. Guinn A. Aucoin D. Accumulation of enrofloxacin and its active metabolite ciprofloxacin in lung tissues of the dog. J. Vet. Intern. Med. 10 1996 165","journal-title":"J. Vet. Intern. Med."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0169-2607(85)90085-9","article-title":"JANA: a new iterative polyexponential curve stripping program.","volume":"20","author":"Dunne A.","year":"1985","unstructured":"Dunne A. JANA: a new iterative polyexponential curve stripping program. Comput. Methods Programs Biomed. 20 1985 269 275","journal-title":"Comput. Methods Programs Biomed."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.2460\/ajvr.1993.54.07.1122","article-title":"Penetration of danofloxacin into the respiratory tract tissues and secretion in calves.","volume":"53","author":"Friis C.","year":"1993","unstructured":"Friis C. Penetration of danofloxacin into the respiratory tract tissues and secretion in calves. Am. J. Vet. Res. 53 1993 1122 1127","journal-title":"Am. J. Vet. Res."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Gibaldi M. Perrier D. Pharmacokinetics. 1982 Marcel Dekker New York N.Y","DOI":"10.1201\/b14095"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1365-2885.1991.tb00854.x","article-title":"Clinical pharmacokinetics of parenterally administered danofloxacin in cattle.","volume":"14","author":"Giles C. J.","year":"1991","unstructured":"Giles C. J. Magonigle R. A. Grimshaw W. T. R. Tanner A. C. Risk J. E. Lynch M. J. Rice J. R. Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J. Vet. Pharmacol. Ther. 14 1991 400 410","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"e_1_3_2_8_2","unstructured":"Gilmour N. J. L. The experimental production of pneumonic pasteurellosis in sheep and calves Experimental bacterial and parasitic infections. Keusch G. Wadstrom T. 1983 269 275 Elsevier New York N.Y"},{"key":"e_1_3_2_9_2","first-page":"529","article-title":"The efficacy of danofloxacin in the therapy of pneumonia associated with Pasteurella species in housed calves.","volume":"97","author":"Grimshaw W. T. R.","year":"1990","unstructured":"Grimshaw W. T. R. Giles C. J. Cooper A. C. Shanks D. J. The efficacy of danofloxacin in the therapy of pneumonia associated with Pasteurella species in housed calves. Dtsch. Tieraerztl. Wochenschr. 97 1990 529 532","journal-title":"Dtsch. Tieraerztl. Wochenschr."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0934-8840(11)80371-3","article-title":"In vitro susceptibility of Pastuerella multocida subspecies multocida strains isolated from swine to 42 antimicrobial agents.","volume":"270","author":"Gutierrez Martin C. B.","year":"1993","unstructured":"Gutierrez Martin C. B. Rodriguez Ferri E. F. In vitro susceptibility of Pastuerella multocida subspecies multocida strains isolated from swine to 42 antimicrobial agents. Zentbl. Bakteriol. 270 1993 387 393","journal-title":"Zentbl. Bakteriol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.2037"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0034-5288(18)31948-9","article-title":"A tissue cage model for the collection of inflammatory exudate in ponies.","volume":"36","author":"Higgins A. J.","year":"1984","unstructured":"Higgins A. J. Lees P. Wright J. A. A tissue cage model for the collection of inflammatory exudate in ponies. Res. Vet. Sci. 36 1984 284 289","journal-title":"Res. Vet. Sci."},{"key":"e_1_3_2_13_2","unstructured":"Highland R. Copeland D. Davidson J. TerHune T. Lechtenberg K. Johnson E. Miles D. Apley M. Wray M. Dose determination and clinical evaluation of the efficacy of enrofloxacin injectable solution in the treatment of bovine respiratory disease Proceedings of the 18th World Buiatrics Congress 1994 627 630"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2885.1995.tb00604.x","article-title":"Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows.","volume":"18","author":"Kaartinen L.","year":"1995","unstructured":"Kaartinen L. Salonen M. Alli L. Pyorala S. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J. Vet. Pharmacol. Ther. 18 1995 357 362","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"e_1_3_2_15_2","unstructured":"Kissane J. M. Bacterial diseases Pathology 7th ed. Anderson W. A. D. Kissane J. M. 1997 369 414 Mosby St. Louis Mo"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0034-5288(93)90065-N","article-title":"Comparison of an HPLC and bioassay method to determine antimicrobial concentrations after intravenous and oral administration of enrofloxacin in four dogs.","volume":"54","author":"K\u00fcng K.","year":"1993","unstructured":"K\u00fcng K. Riond J.-L. Wolffram S. Wanner M. Comparison of an HPLC and bioassay method to determine antimicrobial concentrations after intravenous and oral administration of enrofloxacin in four dogs. Res. Vet. Sci. 54 1993 247 248","journal-title":"Res. Vet. Sci."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1099-081X(199803)19:2<123::AID-BDD89>3.0.CO;2-G","article-title":"Pharmacokinetics and tissue disposition of danofloxacin in sheep.","volume":"19","author":"McKellar Q. A.","year":"1998","unstructured":"McKellar Q. A. Gibson I. F. McCormack R. Z. Pharmacokinetics and tissue disposition of danofloxacin in sheep. Biopharm. Drug Dispos. 19 1998 123 129","journal-title":"Biopharm. Drug Dispos."},{"key":"e_1_3_2_18_2","unstructured":"Pirro F. Scheer M. de Jong A. Additive in vitro activity of enrofloxacin and its main metabolite ciprofloxacin Proceedings of the 14th Annual Congress of the European Society of Veterinary Dermatology and the European College of Veterinary Dermatology 1997 199"},{"key":"e_1_3_2_19_2","unstructured":"Prescott J. F. Baggot J. D. Fluoroquinolones Antimicrobial therapy in veterinary medicine. Prescott J. F. Baggot J. D. 1993 252 262 Iowa State University Press Ames"},{"key":"e_1_3_2_20_2","unstructured":"Richez P. Dellac B. Froyman R. de Jong A. Pharmacokinetics of enrofloxacin in calves and adult cattle after single and repeated subcutaneous injections 6th European Association for Veterinary Pharmacology and Toxicology. Lees P. 1994 232 234 Blackwell Scientific Publications Edinburgh United Kingdom"},{"key":"e_1_3_2_21_2","unstructured":"Scheer M. de Jong A. Concentrations of fluoroquinolones in intestinal tract tissues after intramuscular administration to calves 7th European Association for Veterinary Pharmacology and Toxicology. Anadon A. McKellar Q. 1997 50 51 Blackwell Scientific Publications Edinburgh United Kingdom"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.2.234"},{"key":"e_1_3_2_23_2","first-page":"173","article-title":"The fluoroquinolone antimicrobials: structure antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity.","volume":"80","author":"Vancutsem P. M.","year":"1990","unstructured":"Vancutsem P. M. Babish J. G. Schwark W. S. The fluoroquinolone antimicrobials: structure antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet. 80 1990 173 186","journal-title":"Cornell Vet."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2460\/ajvr.1992.53.12.2315","article-title":"Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs.","volume":"53","author":"Walker R. D.","year":"1992","unstructured":"Walker R. D. Stein G. F. Hauptman J. G. Macdonald K. H. Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am. J. Vet. Res. 53 1992 2315 2319","journal-title":"Am. J. Vet. Res."},{"key":"e_1_3_2_25_2","unstructured":"Watts J. L. Yancey R. J. Jr. Case C. A. Resistance trends in bovine respiratory disease isolates abstr. C-352 Abstracts of the 92nd General Meeting of the American Society for Microbiology. 1992 479 American Society for Microbiology Washington D.C"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.8.1988","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.8.1988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T04:40:14Z","timestamp":1720672814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.43.8.1988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["10.1128\/AAC.43.8.1988"],"URL":"https:\/\/doi.org\/10.1128\/aac.43.8.1988","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,8]]},"assertion":[{"value":"1998-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}